Metabolic vulnerabilities in endometrial cancer

Cancer Research

Volumn 74, Issue 20, 2014, Pages 5832-5845

  Byrne, Frances L ^a,b   Poon, Ivan K H ^c,d   Modesitt, Susan C ^c   Tomsig, Jose L ^a   Chow, Jenny D Y ^a   Healy, Marin E ^a   Baker, William D ^c   Atkins, Kristen A ^a   Lancaster, Johnathan M ^e   Marchion, Douglas C ^e   Moley, Kelle H ^f   Ravichandran, Kodi S ^c   Slack Davis, Jill K ^c,g   Hoehn, Kyle L ^a,b,c,g  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF VIRGINIA   (United States)

^d LA TROBE UNIVERSITY   (Australia)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 FUROIC ACID DERIVATIVE; 3 BROMOPYRUVATE; 5 (TETRADECYLOXY) 2 FUROIC ACID; 6 DIAZO 5 OXONORLEUCINE; DEOXYGLUCOSE; DICHLOROACETIC ACID; ETOMOXIR; METFORMIN; PHLORETIN; PYRUVIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BROMOPYRUVATE; COENZYME A; GLUCOSE TRANSPORTER; HEXOKINASE; PYRUVATE KINASE; REACTIVE OXYGEN METABOLITE; SLC2A9 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; ENDOMETRIUM CANCER; ENDOMETRIUM CELL; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; IN VIVO STUDY; LIPOGENESIS; MIDDLE AGED; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; CASE CONTROL STUDY; CHEMICALLY INDUCED; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; METABOLISM; MOLECULARLY TARGETED THERAPY; NECROSIS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL SURVIVAL; COENZYME A; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLYCOLYSIS; HEXOKINASE; HUMANS; LIPOGENESIS; MICE, NUDE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NECROSIS; PYRUVATE KINASE; PYRUVATES; REACTIVE OXYGEN SPECIES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908125830     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0254     Document Type: Article

References (50)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN2008. Int J Cancer 2010;127:2893-2917.
2. Barlin JN, Wysham WZ, Ferda AM, Khoury-Collado F, Cassella DK, Alektiar KM, et al. Location of disease in patients who die from endometrial cancer: a study of 414 patients from a single institution. Int J Gynecol Cancer 2012;22:1527-31.
3. Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 2010;21:1851-6.
4. Weigelt B, Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol 2012;24:554-63.
5. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-591.
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
7. McCawley GM, Ferriss JS, Geffel D, Northup CJ, Modesitt SC. Cancer in obese women: potential protective impact of bariatric surgery. J Am Coll Surg 2009;208:1093-8.
8. Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I, Hammar N. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control 2011;22:1163-1171.
9. Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W. Cancerincidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003;95:1797-800.
10. Modesitt SC, Geffel DL, Via J, Weltman LA. Morbidly obese women with and without endometrial cancer: are there differences in measured physical fitness, body composition, or hormones? Gynecol Oncol 2012;124:431-6.
11. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
12. Contreras CM, Gurumurthy S, Haynie JM, Shirley LJ, Akbay EA, Wingo SN, et al. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res 2008;68:759-66.
13. Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, et al. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res 2008;14:2543-50.
14. Modesitt SC, Hsu JY, Chowbina SR, Lawrence RT, Hoehn KL. Not all fat is equal: differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer. Int J Gynecol Cancer 2012;22:732-41.
15. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
16. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
17. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.
18. cancergenome.nih.gov [Internet]. Maryland: The Cancer Genome Atlas (TCGA) Research Network; 2014 [updated 2014; cited 2014 Jul 25]. Available from http://cancergenome.nih.gov.
19. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
20. Kasibhatla S, Amarante-Mendes GP, Finucane D, Brunner T, Bossy-Wetzel E, Green DR. Analysis of DNA fragmentation using agarose gel electrophoresis. Cold Spring Harbor Protocols 2006;2006:pdb.prot4429.
21. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols 2008;4:44-57.
22. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009;37:1-13.
23. Hackenberg R, Beck S, Filmer A, Hushmand Nia A, Kunzmann R, Koch M, et al. Androgen responsiveness of the new human endometrial cancer cell line MFE-296. Int J Cancer 1994;57:117-22.
24. Way DL, Grosso DS, Davis JR, Surwit EA, Christian CD. Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture. In Vitro 1983;19:147-58.
25. Doege H, Bocianski A, Joost HG, Schurmann A. Activity and genomic organization of human glucose transporter 9 (GLUT9), a novel member of the family of sugar-transport facilitators predominantly expressed in brain and leucocytes. Biochem J 2000;350:771-6.
26. Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet 2013;45:104-108.
27. Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind J-FH. Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting. Anticancer Res 2013;33:13-20.
28. Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL. A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J Bioenerg Biomembr 2012;44:163-70.
29. Burns KL, Gelbaum LT, Sullards MC, Bostwick DE, May SW. Isocoenzyme A. J Biol Chem 2005;280:16550-8.
30. Kim JS, Ahn KJ, Kim JA, Kim HM, Lee JD, Lee JM, et al. Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: ROS-mediated cell death by 3-BrPA. J Bioenerg Biomembr 2008;40:607-18.
31. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-777.
32. Frolova AI, Moley KH. Glucose transporters in the uterus: an analysis of tissue distribution and proposed physiological roles. Reproduction 2011;142:211-20.
33. Goldman NA, Katz EB, Glenn AS, Weldon RH, Jones JG, Lynch U, et al. GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol 2006;19:1429-36.
34. Knapp P, Chabowski A, Harasiuk D, Gorski J. Reversed glucose and fatty acids transporter expression in human endometrial cancer. Horm Metab Res 2012;44:436-41.
35. Krzeslak A, Wojcik-Krowiranda K, Forma E, Jozwiak P, Romanowicz H, Bienkiewicz A, et al. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res 2012;18:721-8.
36. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654-62.
37. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
38. Ward Patrick S, Thompson Craig B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012;21:297-308.
39. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 2012;18:5856-64.
40. Calvino E, Estan MC, Sanchez-Martin C, Brea R, de Blas E, Boyano-Adanez MC, et al. Regulation of death induction and chemosensitizing action of 3-bromopyruvate in myeloid leukemia cells. energy depletion, oxidative stress, protein kinase activity modulation. J Pharmacol Exp Ther 2013;348:324-35.
41. Cardaci S, Rizza S, Filomeni G, Bernardini R, Bertocchi F, Mattei M, et al. Glutamine deprivation enhances antitumor activity of 3-bromopyruvate through the stabilization of monocarboxylate transporter-1. Cancer Res 2012;72:4526-36.
42. Kim W, Yoon J-H, Jeong J-M, Cheon G-J, Lee T-S, Yang J-I, et al. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther 2007;6:2554-62.
43. Tang Z, Yuan S, Hu Y, Zhang H, Wu W, Zeng Z, et al. Overexpression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester. J Bioenerg Biomembr 2012;44:117-25.
44. Thangaraju M, Karunakaran SK, Itagaki S, Gopal E, Elangovan S, Prasad PD, et al. Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer 2009;115:4655-66.
45. Zhang Q, Pan J, North PE, Yang S, Lubet RA, Wang Y, et al. Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity. Cancer Prev Res 2012;5:717-25.
46. Zhang X, Varin E, Briand M, Allouche S, Heutte N, Schwartz L, et al. Novel therapy for malignant pleural mesothelioma based on antienergetic effect: an experimental study using 3-Bromopyruvate on nude mice. Anticancer Res 2009;29:1443-8.
47. Bielarczyk H, Szutowicz A. Evidence for the regulatory function of synaptoplasmic acetyl-CoA in acetylcholine synthesis in nerve endings. Biochem J 1989;262:377-80.
48. Ricny J, Tucek S. Acetyl coenzyme A and acetylcholine in slices of rat caudate nuclei incubated in the presence of metabolic inhibitors. J Biol Chem 1981;256:4919-23.
49. Leonardi R, Zhang Y-M, Rock CO, Jackowski S. Coenzyme A: back in action. Prog Lipid Res 2005;44:125-153.
50. Qin JZ, Xin H, Nickoloff BJ. 3-Bromopyruvate induces necrotic cell death in sensitive melanomacell lines. Biochem Biophys Res Commun 2010;396:495-500.